RecruitingNCT05984680

COPD Care Pathway Among Patients With Cancer

User-Centered Design of a COPD Care Pathway for Patients With Cancer


Sponsor

Wake Forest University Health Sciences

Enrollment

101 participants

Start Date

Feb 27, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study gathers information for the development of a COPD care pathway for patients with cancer that reduces the treatment burden of patients, implements critical components of COPD care, and overcomes common barriers to COPD care in the community oncology clinic.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • The participant has personal experience with medical management of COPD, defined as meeting at least one of the following criteria:
  • patient with clinical documentation of COPD (either as a confirmed or suspected diagnosis) and has received at least one dose of an immune checkpoint inhibitor for cancer or
  • provider who currently works at least part-time in a medical oncology clinic or
  • provider who works at least part-time to care for patients with known or suspected COPD.
  • A suspected diagnosis of COPD can be based on finding(s) by history, exam, or radiography (e.g., CT changes such as emphysema, bronchial wall thickening, or mucus plugging). A provider is defined as a physician, advanced practice provider, nurse, or respiratory therapist. Study team members are permitted to participate in the study if they meet eligibility criteria.
  • Ability to understand and agree to participate on the study as described by the study information sheet.
  • Capability of speaking or reading English.

Interventions

OTHERObservational Phase 1

Noninterventional study

OTHERObservational Phase 2, Group I

Noninterventional study

OTHERObservational Phase 2, Group II

Noninterventional study

OTHERObservational Phase 3

Noninterventional study


Locations(1)

Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05984680


Related Trials